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Abstract
With favorable pharmacokinetics and binding affinity for avb3 integrin,
18F-labeled dimeric cyclic RGD peptide
([
18F]FPPRGD2) has been intensively used as a PET imaging probe for lesion detection and therapy response monitoring.
A recently introduced kit formulation method, which uses an
18F-fluoride-aluminum complex labeled RGD tracer ([
18F]AlF-
NOTA-PRGD2), provides a strategy for simplifying the labeling procedure to facilitate clinical translation. Meanwhile, an
easy-to-prepare
68Ga-labeled NOTA-PRGD2 has also been reported to have promising properties for imaging integrin avb3.
The purpose of this study is to quantitatively compare the pharmacokinetic parameters of [
18F]FPPRGD2, [
18F]AlF-NOTA-
PRGD2, and [
68Ga]Ga-NOTA-PRGD2. U87MG tumor-bearing mice underwent 60-min dynamic PET scans following the
injection of three tracers. Kinetic parameters were calculated using Logan graphical analysis with reference tissue.
Parametric maps were generated using voxel-level modeling. All three compounds showed high binding potential
(BpND=k 3/k4) in tumor voxels. [
18F]AlF-NOTA-PRGD2 showed comparable BpND value (3.7560.65) with those of
[
18F]FPPRGD2 (3.3960.84) and [
68Ga]Ga-NOTA-PRGD2 (3.0960.21) (p.0.05). Little difference was found in volume of
distribution (VT) among these three RGD tracers in tumor, liver and muscle. Parametric maps showed similar kinetic
parameters for all three tracers. We also demonstrated that the impact of non-specific binding could be eliminated in the
kinetic analysis. Consequently, kinetic parameter estimation showed more comparable results among groups than static
image analysis. In conclusion, [
18F]AlF-NOTA-PRGD2 and [
68Ga]Ga-NOTA-PRGD2 have comparable pharmacokinetics and
quantitative parameters compared to those of [
18F]FPPRGD2. Despite the apparent difference in tumor uptake (%ID/g
determined from static images) and clearance pattern, the actual specific binding component extrapolated from kinetic
modeling appears to be comparable for all three dimeric RGD tracers.
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Introduction
Members of integrin family play an important role in the
regulation of cellular activation, survival and migration. Integrin
facilitates the vascular cell proliferation which is necessary for
tumor growth and metastasis [1–4]. Among the integrin receptor
subtypes, avb3 is one of the most important members because of its
involvement in tumor angiogenesis and metastasis. Therefore,
quantification of tumor integrin avb3 level by non-invasive PET
imaging has become an important tool for tumor diagnosis and
treatment monitoring in both pre-clinical and clinical studies [5–
8]. Great efforts have been made in developing radiolabeled
integrin targeting agents [6,9–12]. A variety of arginine-glycine-
aspartic (RGD)-based probes have been made and investigated,
since the cyclic RGD containing peptides have high affinity and
selectivity for integrin avb3. It has also been well documented that
dimeric and multimeric RGD peptides are superior to the
monomeric analogs [9,13], most likely due to the polyvalency
effect. RGD peptides have been radiolabeled and evaluated with
18F [14],
64Cu [15],
68Ga [16,17],
76Br [12] and
89Zr [18] for
integrin avb3 targeted PET imaging. A number of
18F-labeled
RGD peptide tracers have been tested in oncologic patients,
including [
18F]galacto-RGD [6], [
18F]AH11585 [19] and
[
18F]FPPRGD2 [20]. However, all these compounds suffer from
multistep time consuming and low yield synthetic procedures,
limiting their widespread use as routine tracers in the clinic.
Recently, major advances have been made in simplifying
18F-
labeled bioactive molecules [21–24]. The fluorophilic nature of
aluminum is most attractive since it affords direct aqueous
18F-
labeling by the formation of stable aluminum fluoride chelates.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37506Previously we have successfully synthesized [
18F]AlF-NOTA-
PRGD2 through a kit formulation without the need of HPLC
purification. The tracer showed high specific activity and has been
tested in both xenograft [25] and myocardial infarct [26] models.
NOTA-RGD conjugates have also been labeled with
68Ga, a
generator based PET radionuclide [16,17].
Visual inspection and simple standardized uptake value (SUV)
assessment are insufficient to properly analyze the data acquired
from a variety of tracers with different kinetic properties [27].
Moreover, when used for the evaluation of pharmacokinetic
properties of a drug or tracer, quantitative data analysis from
dynamic imaging can provide necessary parameters such as peak
time, clearance rate, binding potential and volumes of distribution.
Kinetic modeling with graphical analysis provides a visual way to
distinguish different types of tracer accumulation in the initial
studies of new ligands. Kinetic modeling is reliable and
independent on scan duration and plasma clearance, and
therefore is considered to be more favorable than SUV in the
data analysis.
Logan graphical analysis is a widely accepted method for
reversible tracer kinetic analysis [28]. It provides an estimate of the
Distribution Volume, DV, by a simple plot without the necessity of
specifying a particular tissue model [29]. It also shows marked
advantages for generating kinetic parametric images because of its
fast computation speed and robust performance over the high level
noise in the time-activity curves of individual PET image voxels.
Consequently, graphical analysis (GA) methods are particularly
suitable for characterizing the kinetics of a new tracer.
Similar to kinetic modeling using nonlinear least square
method, the regular GA method also requires arterial blood
sampling in order to obtain accurate input function. In some
instances, e.g. receptor binding study, a reference region can be
employed in place of arterial plasma input if it is devoid of the
specific binding sites [30,31]. The DV ratio (DVR) derived from
reference tissue model generally provides better reproducibility
than either the DV or the recepter parameter k3 [29]. The binding
potential (BpND=DVR-1) of tracer can be calculated on a voxel-
by-voxel basis and used for voxel-wise comparison. Herein, we
applied Logan graphical analysis with reference tissue to perform
comparisons of pharmacokinetics between the more readily
synthesized [
18F]AlF-NOTA-PRGD2 and [
68Ga]Ga-NOTA-
PRGD2, and the previously established radioligand
[
18F]FPPRGD2 (Figs. 1 and 2).
Results
Time-activity curves
Sixty-minute dynamic PET scans were performed to evaluate
the pharmacokinetics and kinetic parameters for tumor targeting
of [
18F]AlF-NOTA-PRGD2, [
18F]FPPRGD2 and [
68Ga]Ga-
NOTA-PRGD2. The time-activity curves were illustrated for the
U87MG tumor (Fig. 3) and for the liver, kidneys and heart
(Fig. 4).
For all three RGD probes, radioactivity accumulated rapidly in
the tumor and remained high uptake throughout the dynamic scan
period. All three tracers showed rapid and high initial kidney
accumulation, reaching peak value at around 5 min after
injection, followed by rapid clearance from the renal system over
time. Other normal organs such as liver and heart showed a peak
at early time points (,1 min) because of blood perfusion with high
concentration of radioactivity. The uptakes in these regions
dropped rapidly afterwards, which is consistent with a previous
report [32].
Quantification of static images
The quantification of three RGD tracers in tumor and main
organs including liver, kidneys, and muscle were obtained from
image at 1-h time point, which is the last frame of dynamic image
series. The U87MG tumors were clearly identified with all three
RGD tracers. The quantitative uptake values in tumor and other
main organs were summarized in Table 1, shown as %ID/g. The
tumor uptake of [
18F]AlF-NOTA-PRGD2 was 3.4560.18%ID/g
(n=4), which is significantly higher than that of either
[
18F]FPPRGD2 (2.9160.35%ID/g, n=4, p,0.05) or [
68Ga]Ga-
NOTA-PRGD2 (2.4260.56%ID/g, p,0.05). Although all three
groups showed relatively high kidney accumulation at 1-h time
point, [
18F]AlF-NOTA-PRGD2 showed much higher kidney
uptake than the other two tracers (p,0.05). As shown in
Table 1,[
18F]AlF-NOTA-PRGD2 had significantly higher
kidney uptake (4.6761.08%ID/g) at 1-h time point than the
other two RGD dimers ([
18F]FPPRGD2: 2.7860.58%ID/g,
n=4, p=0.029; [
68Ga]Ga-NOTA-PRGD2: 2.6260.98%ID/g,
p=0.033). At the same time, all three tracers had relatively low
liver uptake and no statistical difference was found among groups
(p.0.05).
Kinetic parameters estimation
Quantitative analysis and kinetic parameter estimation were
performed by fitting the time-activity curves derived from 60-min
dynamic PET data. To compare BpND of all three RGD tracers
for tumor targeting, Logan graphical analysis was performed using
muscle as reference tissue. Figure 5 shows the linear regression of
normalized integration of tumor ROI and that of reference tissue
(muscle) ROI. The best linear correlation was achieved when the
exchange between tissue and plasma reached equilibrium
(t*.30 min). The slope of the regression line was DVR and the
BpND (DVR-1) values of each tracer were computed. As shown in
Figure 6a,[
18F]AlF-NOTA-PRGD2 had slightly higher BpND
(3.7560.65) in tumor than those of [
18F]FPPRGD2 (3.3960.84)
and [
68Ga]Ga-NOTA-PRGD2 (3.0960.21), but the difference is
not significant (p.0.05).
VT was calculated according to Logan graphical analysis with
image-derived input function. In the tumor region, VT could be
separated into non-displaceable and specific binding components
to enable accurate assessment of the magnitude of specific binding
of all three RGD compounds. Figure 6b plots the mean 6 SD of
the total VT, specific VS and non-specific VND components of each
tracer in tumor. VS was found to be the dominant component of
the total distribution volume in each group. [
18F]AlF-NOTA-
PRGD2 showed slightly higher VS (1.9260.26) than those of
[
18F]FPPRGD2 (1.7960.15) and [
68Ga]Ga-NOTA-PRGD2
(1.5060.12), but no significant difference was found among them
(p.0.05). Little difference in VND was found among different
groups. To further compare the quantitative distribution of whole
body organs, VT of tumor, kidneys, muscle, and liver were also
calculated and illustrated in Figure 6c. The mean and SD value
of each macro-parameter were summarized in Table 1. Unlike
the uptake calculated from static images, little difference was found
in VT among three RGD tracers in the tumor, liver and muscle.
Meanwhile, VT of [
18F]AlF-NOTA-PRGD2 (5.2460.24) in
kidneys was higher than those of [
18F]FPPRGD2 (4.1060.27,
n=4, p=0.002) and [
68Ga]Ga-NOTA-PRGD2 (3.3760.56,
n=4, p=0.006), which correlated to the static analysis.
Parametric mapping
Parametric maps of VT and BpND were generated at voxel level
by fitting the Logan graphical model to the time-activity curves of
each voxel of the dynamic PET image series (Fig. 7). In BpND
Reference Tissue Model Analysis of RGDs
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18F]AlF-NOTA-PRGD2 showed comparable BpND value
in the tumor region with [
18F]FPPRGD2 and [
68Ga]Ga-NOTA-
PRGD2. In the VT parametric maps, all three tracers showed very
similar volume of distributions in normal organs. BpND maps also
provided higher tumor-to-muscle contrast than the original static
images for all three tracers. Compared with original static PET
images at 60 min, parametric maps showed more comparable
tumor region value, which is consistent with the quantification
from static image analysis and kinetic parameter estimation.
Discussion
Several groups, including ours, have pursued a straightforward
and relatively high yield one-step RGD labeling procedure for pre-
clinical and clinical applications. The preparation of [
18F]AlF-
NOTA-PRGD2 has been described in previous reports [25,32]. In
static image analysis, the quantification of tissue uptake, expressed
as %ID/g has been well established and widely used in the
quantification of molecular imaging. Other than the binding
affinity of receptors, the uptake of a given radiotracer determined
from static images at a particular time point can be affected not
only by several microenvironment factors, such as the variance of
blood perfusion, heterogeneous vascular permeability, but also by
the pharmacokinetics in the body, for instance, the whole body
blood circulation, clearance pattern from renal system, and tracer
washout rate in the target tissue. Thus, kinetic modeling with
dynamic imaging, which can provide tracer pharmacokinetic
information and separate the actual specific binding component
from total tracer uptake in tissue, will significantly facilitate the
molecular probe pharmacokinetic evaluation. In this study, we
evaluated the [
18F]AlF-NOTA-PRGD2 using kinetic modeling in
U87MG xenografts model and generated whole-body parametric
maps with voxel level modeling for the first time. We compared
the kinetic parameters with the well-established RGD dimer
[
18F]FPPRGD2 and another rapidly labeled RGD tracer
68Ga-
NOTA-PRGD2.
Compared with static image analysis, dynamic PET imaging
followed by kinetic estimation provides the time course of various
organs and the quantitative characterization of tracer pharmaco-
kinetics. Based on the compartment model, RGD tracer accumu-
lation in the tumor region can be separated into three
components: tracer in arterial plasma, non-specific or specific
Figure 1. Chemical structures of three dimeric RGD peptides [
18F]FPPRGD2, [
68Ga]Ga-NOTA-PRGD2 and [
18F]AlF-NOTA-PRGD2.
doi:10.1371/journal.pone.0037506.g001
Figure 2. The three-compartment model describing RGD tracer
kinetics in tumor and the two-compartment model describing
RGD tracer kinetics in reference tissue. Cp represents tracer
concentration in arterial blood plasma. Ct represents the free or non-
specific binding of tracer in interstitial and intracellular space. Cm
represents the portion of RGD tracer bound specifically to integrin. K1,
k2,k 3 and k4 are the transport and binding rates of the tracer. K1 [ml/g/
min] reflects the perfusion rate into tissue. k2 [1/min] represents the
clearance rate from plasma. k3 [1/min] is the specific binding rate and k4
[1/min] is the dissociation rate.
doi:10.1371/journal.pone.0037506.g002
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plasma, interstitial space or tumor cells. The kinetic parameters
(kc) reflect the exchange rates between compartments representing
the intravascular, extravascular or interstitial, and intracellular
transportation rate. By fitting the time-activity curves of dynamic
PET data to the three-compartment model, non-specific and
specific binding can be separated from the total tumor uptake and
the actual specific binding affinity can be revealed. In the static
image analysis, [
18F]AlF-NOTA-PRGD2 (3.4560.18%ID/g,
n=4) showed significantly higher tumor uptake than that of
[
18F]FPPRGD2 (2.9160.35%ID/g, n=4, p=0.032) and [
68Ga]-
Ga-NOTA-PRGD2 (2.4260.56%ID/g, p=0.012), which is
consistent with the previous study [25]. However, the kinetic
analysis demonstrated that [
18F]AlF-NOTA-PRGD2 had compa-
rable binding affinity with the other two RGD dimer peptides and
no significant difference was found in either BpND or VT of the
three RGD compounds (p.0.05). The parametric imaging also
showed more comparable kinetic parameter values than the
original static images in the tumor, which correlated well with the
quantification of macro-parameters. Considering several factors
contributing to static tumor uptake, the relatively higher value of
Figure 3. Tumor time-activity curves derived from 60-min
dynamic PET scans of mice after administration of dimeric RGD
peptide tracers. (a)[
18F]AlF-NOTA-PRGD2, (b)[
18F]FPPRGD2, and (c)
[
68Ga]Ga-NOTA-PRGD2 (n=4/group).
doi:10.1371/journal.pone.0037506.g003 Figure 4. Representative time-activity curves of major organs
(kidneys, heart, tumor and liver) derived from 60-min dynamic
PET scans after administration of dimeric RGD peptide tracers.
(a)[
18F]AlF-NOTA-PRGD2, (b)[
18F]FPPRGD2, and (c)[
68Ga]Ga-NOTA-
PRGD2 (n=4/group).
doi:10.1371/journal.pone.0037506.g004
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18F]AlF-NOTA-PRGD2 uptake may be a consequence of more
non-specific accumulation and lower clearance rate from plasma.
For [
18F]FPPRGD2, the PEGylation improved the properties by
reducing the renal retention of compounds [25]. According to the
time-activity curves in kidneys, [
68Ga]Ga-NOTA-PRGD2 showed
faster renal clearance and correlated with the observation of fast
washout in the plasma. Thus, kinetic modeling would eliminate
the impact of non-specific binding that may be caused by blood
flow, permeability variance and different interstitial fluid pressure.
In this study, despite of the apparent difference in tumor uptake
and clearance pattern, the actual specific binding in tumor region,
which has been extrapolated from the kinetic modeling, appears to
be similar.
Although no significant difference was found in kinetic
parameters among all three RGD peptide tracers, [
18F]AlF-
NOTA-PRGD2 still showed a slightly higher BpND and Vs in the
tumor, and the lowest values were observed in the [
68Ga]Ga-
NOTA-PRGD2 group, as shown in Figure 6a–b. Because of the
similar binding affinity and integrin expression level among all the
tested animals, the difference between BpND and specific volume
of distribution may be a consequence of variance of specific
activity ([
18F]AlF-NOTA-PRGD2.[
18F]FPPRGD2.[
68Ga]Ga-
NOTA-PRGD2 at the end of synthesis).
The pharmacokinetic analysis of RGD compounds has been
conducted with
64Cu-DOTA-RGD [33], [
18F]FPPRGD2 [34],
and
18F-galacto-RGD [35] in preclinical or clinical studies. In our
previous study, we used the Logan graphical analysis with
reference tissue model to fit the dynamic time activity curves
(TACs) for
18F-labeled RGD tracers [36]. These studies have
implied that the RGD kinetics agrees with a reversible three-
compartment model. Although Ferl et al. [33] conducted
pharmacokinetic analysis of
64Cu-DOTA-RGD in preclinical
models and demonstrated that a 2-tissue compartment, 4-
parameter model with internalization was more appropriate to
describe RGD tracer kinetics, the internalization of RGD tracer
did not play a key role in the kinetic modeling especially for early
time points (,60 min). Herein, we apply the kinetic analysis using
Logan graphical analysis with reference tissue model based on the
3-compartment reversible model.
Table 1. Estimated parameter values from static images and kinetic modeling.
Tumor Kidneys Muscle Liver
Tissue uptake (%ID/g) [
18F]AlF-NOTA-PRGD2 3.4560.18 4.6761.08 0.5360.11 1.2160.54
[
18F]FPPRGD2 2.9160.35 2.7860.58 0.3660.089 1.1060.18
(p=0.033) (p=0.029) (p=0.110) (p=0.720)
[
68Ga]Ga-NOTA-PRGD2 2.4560.56 2.6260.98 0.6060.11 1.3660.28
(p=0.012) (p=0.033) (p=0.500) (p=0.590)
Volume of Distribution (VT)[
18F]AlF-NOTA-PRGD2 2.6560.34 5.2460.24 0.5360.086 1.2360.085
[
18F]FPPRGD2 2.3560.22 4.1060.27 0.4460.071 0.9760.14
(p=0.370) (p=0.002) (p=0.130) (p=0.015)
[
68Ga]Ga-NOTA-PRGD2 2.0760.12 3.3760.56 0.5760.064 1.2460.11
(p=0.110) (p=0.006) (p=0.440) (p=0.900)
P values indicate the significance of difference between [
18F]AlF-NOTA-PRGD2 and the other two tracers respectively.
doi:10.1371/journal.pone.0037506.t001
Figure 5. Logan graphical analysis fitting to 60-min dynamic microPET data, which showed excellent linearity of normalized
integrated (Int) tumor activity vs. normalized integrated muscle tissue activity effective for time .30 min. Slopes of fits represent
DVRs.
doi:10.1371/journal.pone.0037506.g005
Reference Tissue Model Analysis of RGDs
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37506Considering the reasonable signal to noise ratio of dynamic
PET data, we conducted model fitting and kinetic parameter
estimation using linear regression. Similar to the GA with arterial
plasma input function form, the reference region method is
susceptible to noise. The main problem with GA is the bias in the
estimated parameters due to noise [29]. Several multiple linear
regression methods have been proposed to reduce such bias and
improve the accuracy of parameter estimation, e.g. Ichise et. al.
[37], Zhou et. al. [38,39]. In the future, we will apply an average
of values determined from some subset of these different methods
to reduce the bias and variability, and may achieve superior results
than applying any one of them [29] alone.
In conclusion, [
18F]AlF-NOTA-PRGD2 and [
68Ga]Ga-NO-
TA-PRGD2 have comparable pharmacokinetics and quantitative
parameters compared to those of [
18F]FPPRGD2. Despite the
apparent difference in tumor uptake and clearance pattern, the
actual specific binding extrapolated from the kinetic modeling
appears to be comparable for all three RGD tracers. The satisfying
performance in the whole body kinetic estimation and easy
labeling procedure suggest that [
18F]AlF-NOTA-PRGD2 is a
promising alternative to [
18F]FPPRGD2 for integrin targeting
with PET.
Materials and Methods
The
68Ge/
68Ga generator was purchased from iThemba Labs
(South Africa) and
18F-fluoride was obtained from the NIH
cyclotron facility. [
18F]FPPRGD2, [
68Ga]Ga-NOTA-PRGD2 and
[
18F]AlF-NOTA-PRGD2 (Fig. 1) were prepared according to a
published procedure [25].
Preparation of animal tumor models
The U87MG human glioblastoma tumor model, which has
been documented to express high level of integrin avb3 [32], was
selected for PET imaging. The U87MG cells obtained from
ATCC (Manassas, VA) were cultured in DMEM medium
supplemented with 10% fetal bovine serum (FBS), 100 IU/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen), and in a
humidified atmosphere containing 5% CO2 at 37uC. The
xenografted model was established by inoculation of 5610
6 cells
into the left shoulder of each female athymic nude mouse at 5–6
weeks of age (Harlan Laboratories). Tumor growth was monitored
by caliper measurements of perpendicular axes of the tumor three
times a week after the tumors are palpable. The tumor volume was
determined as the formula: V=a6(b
2)/2, where a and b are the
length and width of each tumor, respectively, in mm. The U87MG
xenografted mice underwent PET imaging when the tumor
volume reached about 300 mm
3 (about 3 weeks after inoculation).
This study was approved by the NIH Clinical Center Animal Care
and Use Committee (ACUC). Moreover, all mice were maintained
in a specific pathogen-free facility in accordance with the
requirements of the ACUC.
Dynamic PET imaging
Dynamic PET data acquisition was performed using an Inveon
microPET scanner (Siemens Medical Solutions). With the
assistance of the Inveon system’s positioning laser, U87MG
tumor-bearing mouse was placed with its tumor located at the
center of field of view (FOV), where the highest imaging sensitivity
can be achieved. Sixty-minute dynamic PET scans were
performed after tail-vein injection of ,3.7 MBq (100 mCi) of
Figure 6. (a) Binding potential (BpND)o f
18F-labeled RGD peptide tracers. (b) Volumes of distribution (VT)o f
18F-labeled RGD peptide tracers. The
BpND was calculated as k3/k4 reflecting the binding affinity, and the volume of distribution (VT=K 1/k2(1+k3/k4)) reflects the tissue-to-plasma
concentration ratio. VT can be regarded as the sum of specific (VS=K 1?k3/(k2?k4)) and nonspecific (VND=K 1/k2) distribution. (c) Volume of distribution
of tumor, kidneys, muscle and liver.
doi:10.1371/journal.pone.0037506.g006
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18F]AlF-NOTA-PRGD2, [
18F]FPPRGD2 or [
68Ga]-
Ga-NOTA-PRGD2, n=4/group) under isoflurane anesthesia.
During the acquisition period, a thermostat-controlled thermal
heater maintained the body temperature of mice. PET images
were reconstructed with 2 iterations of 3-dimensional ordered-
subsets expectation maximum (3D OSEM) with 14 subsets,
followed by 18 iterations of maximum a posteriori (MAP)
algorithm with a smoothing parameter of 0.1 (frame rates:
10630 s, 5660 s, 56120 s and 106240 s). No attenuation
correction was performed in this study.
ROI quantification and derivation of time-activity curves
In the dynamic PET image analysis, regions of interest (ROIs)
were measured with the Inveon Research Workplace (IRW) 3.0
software. ROI was determined by manually superimposing the
ellipsoid volume of interest (VOI) to the target tissue on the last
frame of the entire 60-min dynamic image sequence. Then a
threshold of 30% maximum was set to screen the voxels with lower
values in the entire VOI because of possible tumor heterogeneity
and shape irregularity. The time–activity curves were derived by
superimposing the same VOI on each time frame of the entire 60-
min dynamic image sequence and the value of each time point
represents the overall concentration of radioactivity in the tissue.
The activity concentrations were determined by the mean pixel
intensity within each VOI, which were converted to mCi/ml using
a calibration constant. Assuming the tissue density of 1 g/ml, the
ROI activity was converted to mCi/g and normalized as percent
injected dose per gram (%ID/g). The tissue uptake quantification
of static scan at 60 min was determined from the last frame of
dynamic images. The arterial blood input function was estimated
by drawing a VOI in the region of left ventricle on the
reconstructed PET image at the 0.5 min time point (the second
frame of dynamic PET image series). The region of muscle
contralateral to the tumor was selected as the reference tissue.
Kinetic modeling and parameter estimation
Kinetic analysis of regional TACs was performed based on two-
tissue (three-compartment) and one-tissue (two-compartment)
model (Fig. 2). The three-compartment model consists of
unmetabolized radiotracer in arterial blood plasma (Cp), free or
non-specific binding tracer in interstitial and intracellular space
(Ct), and tracer bound specifically to integrin (Cm). Both Ct and
Cm occupy the same physical volume. The ROI(t) represents the
sum of radioactivity from all compartments and includes the
plasma volume fraction. Similarly, the two-compartment model
describes RGD tracer kinetics using muscle as reference tissue and
Ctref represents free (non-specific binding) tracer in the reference
tissue (muscle) region. Generally speaking, kinetic parameters K1
[ml/g/min], k2 [1/min], k3 [1/min], k4 [1/min] represent the
transport or binding rates of plasma perfusion into tissue,
clearance from plasma, specific binding and dissociation, respec-
tively.
Based on Logan plot shown in Eq. 1 [28,33], the ratio between
the integral of Cp(t) and the instantaneous value of ROI(t), and the
ratio between the integral and the instantaneous value of ROI(t)
become linearly related when the exchange between the target
tissue and plasma reaches an equilibrium (t.t*).
Ð T
0
ROI(t)dt
ROI(T)
~DV
Ð T
0
Cp(t)dt
ROI(T)
zInt twt  ðÞ ð 1Þ
DV denotes the distribution volume and can be easily calculated
from the linear regression. DV is a measure of the capacity of
tissue to bind a particular tracer and can be regarded as the sum of
specific (VS) and nonspecific distribution (VND).
VS~
K1:k3
k2:k4
ð2Þ
VND~
K1
k2
ð3Þ
Figure 7. Representative original static PET images at 60 min
(left), parametric maps of volume of distribution (middle) and
binding potential (right) for RGD peptide tracers. (a)[
18F]AlF-
NOTA-PRGD2, (b)[
18F]FPPRGD2, and (c)[
68Ga]Ga-NOTA-PRGD2. The
arrows point to tumors.
doi:10.1371/journal.pone.0037506.g007
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VT~VSzVND~
K1
k2
(1z
k3
k4
) ð4Þ
K1,k 2,k 3, and k4 are calculated by linear fitting to 60-min
dynamic PET data [34].
In the original Logan plot estimation, arterial blood input
function is required. Unfortunately, blood sampling faces technical
challenges and brings radiation exposure to researchers. A
reformulation of the Logan analysis, which uses a reference
region, provides the possibility to estimate the kinetic parameters
without arterial blood sampling [31]. We select muscle as the
reference tissue because of its negligible integrin expression and
have the relationship between muscle and plasma expressed in
equation 5.
Ð T
0
ref(t)dt
ref(T)
~DVref
Ð T
0
Cp(t)dt
ref(T)
z
1
kref
2
ð5Þ
Thus, the normalized integral of activity in the tumor versus the
normalized integral of activity in the muscle becomes linear
according to Eq.6:
Ð T
0
ROI(t)dt
ROI(T)
~DVR
Ð T
0
ref(t)dtzref(t)=k
ref
2
ROI(T)
0
B B B @
1
C C C A
zInt0 ð6Þ
The ratio of integrated tumor uptake and tumor uptake was set as
the y-axis. The ratio of integrated reference tissue uptake and
tumor uptake was set as the x-axis in Logan plot. The slope of the
linear portion of the Logan plot is distribution volume ratio
(DVR). Binding potential (BpND=k 3/k4), a macro-parameter
reflecting the binding affinity in vivo, could be derived from
DVR (BpND=DVR-1).
Parametric map estimation
Voxel-wise parametric mapping was generated for whole body
image using Logan plot. Logan graphical analysis with input
function was performed to calculate VT at voxel level using Eq. 1.
Reference tissue model was applied for BpND map according to
Eq. 5 and 6 [34,35].
Statistical Analysis
Quantitative kinetic parameters determined from dynamic PET
data were expressed as mean 6 SD. Differences between either
parameters derived from static images and kinetic analysis or
kinetic parameters among all three RGD groups were evaluated
using unpaired Student t test. P values less than 0.05 were
considered statistically significant.
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